Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Oct:68:152529.
doi: 10.1016/j.semarthrit.2024.152529. Epub 2024 Aug 8.

Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network

Affiliations
Multicenter Study

Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network

Fabricio Espinosa-Ortega et al. Semin Arthritis Rheum. 2024 Oct.

Abstract

Objective: To study the trajectories of changes in damage over time and explore associations with autoantibody defined subgroups using a large international cohort of patients with idiopathic inflammatory myopathies (IIM).

Methods: Data from the MYONET registry, including patients who were tested for autoantibodies and had at least one assessment of damage using the Myositis Damage Index (MDI), were analyzed. Patients were sub-grouped according to their autoantibody profiles (myositis-specific, myositis-associated, or seronegative). The index date was defined as the time point for the first registered MDI assessment. The longitudinal trajectories of damage with autoantibody status as the main predictor were analyzed using linear mixed models.

Results: A total of 757 adult patients were included in this study. Each year of disease duration since diagnosis had an estimated MDI score increase of 0.16 units for the seronegative group (reference). Compared with the seronegative group as reference, patients with dermatomyositis-specific autoantibodies developed less damage per year of follow-up since diagnosis (average 0.08 less score, P = 0.04), whereas patients with anti-PM/Scl autoantibodies developed more damage per year of follow-up since diagnosis (average 0.28 higher score, P = 0.03) independent of sex and age at diagnosis. The seronegative subgroup and the immune-mediated necrotizing myopathy autoantibody subgroup had the strongest correlation between severity of muscle damage and HAQ-DI scores at five years of follow-up, rho=0.84, P < 0.001 and rho=0.72, P < 0.001, respectively.

Conclusion: Our study is the first to describe patterns and trajectories of change in damage over time in relation to autoantibody defined subgroups in a large international multicenter cohort of patients with IIM. Patients with anti-PM/Scl scored a greater extent of damage, whereas patients with dermatomyositis-specific antibodies had less damage than seronegative patients. Severity in muscle damage had moderate to strong correlation with functional disability among the IMNM and seronegative subgroups with lower correlations for the other subgroups. These findings suggest that autoantibodies may be useful predictors of long-term damage.

Keywords: Autoantibodies; Dermatomyositis; Inflammatory myopathies; Myositis; Organ damage.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ingrid E Lundberg, Louise Diederichsen reports a relationship with Boehringer Ingelheim Pharmaceuticals Inc that includes: consulting or advisory. Ingrid E Lundberg reports a relationship with Astra Zeneca that includes: board membership. Ingrid E Lundberg, Jiri Vencovsky, reports a relationship with EMD Serono Inc that includes: funding grants. Ingrid E Lundberg, Marianne de Visser reports a relationship with Novartis that includes: consulting or advisory. Ingrid E Lundberg reports a relationship with Pfizer that includes: consulting or advisory. Ingrid E Lundberg reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Hector Chinoy reports a relationship with UCB Inc that includes: speaking and lecture fees. Hector Chinoy reports a relationship with GlaxoSmithKline Inc that includes: speaking and lecture fees. Ingrid E Lundberg, Louise Diederichsen reports a relationship with Boehringer Ingelheim Pharmaceuticals Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types

LinkOut - more resources